Navigation Links
Early cessation of breastfeeding by HIV+ women in poor countries and child survival
Date:7/24/2008

July 24, 2008 A new study by researchers from Columbia University's Mailman School of Public Health addresses one of the most challenging issues in infant health and preventing mother-to-child HIV transmission in poor countries. In these settings, HIV-infected mothers had been advised that for the best outcome for their infants, they should exclusively breast-feed, followed by a rapid weaning four to six months after birth. But according to the study conducted in Lusaka, Zambia by Mailman School researchers, which was published in the July 10 issue of the New England Journal of Medicine, abrupt cessation of breast-feeding by HIV+ mothers after the first four months of life did not result in any statistically significant benefit to infants in terms of HIV-free survival at 24 months, compared to those infants who were weaned at an average of 16 months of age (68.4% versus 64%). A further finding from the study indicated that infants who were HIV+ at four months of age had significantly higher death rates by 24 months if they were abruptly weaned than if breast-feeding were continued (74% versus 55%).

Among infants who were breast- fed and not infected with HIV at four months, there was no statistically significant difference in HIV-free survival at 24 months 84 percent for those who stopped breast- feeding early compared to 81 percent who continued to breast- feed.

The study included 958 women with HIV and their infants. The proportion of new HIV infections between four and 24 months was not significantly different between the children whose mother abruptly stopped breast-feeding and those whose mothers continued to breast-feed indefinitely, and no significant differences were found in survival between them. Seventy-six percent of infants whose mothers stopped breast-feeding at four months survived to 24 months of age versus 75 percent of infants whose mothers continued breast- feeding for as long as the women chose. Four months wa
'/>"/>

Contact: Stephanie Berger
sb2247@columbia.edu
212-305-4372
Columbia University's Mailman School of Public Health
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. 60 second test could help early diagnosis of common brain diseases
2. Restless legs syndrome affects nearly 2 percent of US/UK children
3. Bleeding, not inflammation, is major cause of early lung infection death
4. Pig study sheds new light on the colonisation of Europe by early farmers
5. Color contrast is seen by the brain early doors
6. Extra gene copies were enough to make early humans mouths water
7. Was ability to run early mans Achilles heel?
8. New technique can be breakthrough for early cancer diagnosis
9. Yam bean a nearly forgotten crop
10. NIH awards nearly $23M to University of Chicago for translational research
11. Yam bean a nearly forgotten crop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... training video produced by Rafael Ortega, MD, the vice-chair ... Boston Medical Center (BMC) and professor of anesthesiology at ... is featured in this week,s New England Journal ... is the fifth BMC-produced video to appear in the ...
... After 30 years with Chip Supply, Inc., President ... Perrott served in various capacities through the ... tenure, Chip Supply grew into the largest independent die ... global provider of high reliability interconnect solutions, serving the ...
... BUFFALO, NY -- Exposure to air pollution early in life ... may alter her DNA and may be associated with premenopausal ... Buffalo have shown. The findings indicated that higher air ... increase levels of E-cadherin, a protein important to the adhesion ...
Cached Biology News:Pulse oximetry training video by BMC anesthesiologist published in NEJM 2Air pollution exposure affects chances of developing premenopausal breast cancer 2
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation ... executive promotions as well as changes to Martine ... Executive Promotions United Therapeutics announced the ... and Co-Chief Executive Officer and David Zaccardelli , ... In connection with these promotions, Dr. Rothblatt,s title will ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
(Date:12/15/2014)... BEIJING , Dec. 15, 2014  Origin Agritech Limited ... "), a technology-focused supplier of crop seeds in ... results for its fiscal year 2014 ended September 30, 2014, ... The Company will host a teleconference on January 8, ... Beijing time to discuss the results. To participate ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... 18 Martek Biosciences,(Nasdaq: MATK ) announced today ... patented, vegetarian form of DHA omega-3 for brain, eye,and ... vegetarian DHA,Oroweat 9 Grain Bread with life,sDHA from Bimbo ... Pacific Northwest, California, Arizona,and Nevada., "This new launch ...
... Baxter,International Inc. (NYSE: BAX ) announced today ... an additional $2 billion of the company,s,common stock to ... authorization., Baxter has less than $700 million of ... that was authorized in March,2007. Shares will be repurchased ...
... Calif., March 18 TorreyPines Therapeutics,Inc. (Nasdaq: ... Phase II study of,NGX267, a muscarinic agonist in ... syndrome., The company is conducting a randomized, ... to evaluate,the safety, tolerability and efficacy of this ...
Cached Biology Technology:Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 2Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 3Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4
Tube-O-DIALYZER Floats, small....
Nestin, Human...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
Biology Products: